AAAAAA

   
Results: 1-25 | 26-50 | 51-51
Results: 1-25/51
IMPACT OF DONOR LYMPHOCYTE INFUSION FOR HEMATOLOGICAL MALIGNANCY RELAPSED AFTER ALLOGENEIC BONE-MARROW TRANSPLANTATION
Authors: ZEDER K WALLER EK REDEI I CONNAGHAN DG FLEMING WH GELLER RB HEFFNER LT HILLYER CD HOLDEN J HOLLAND K JONES W MCCOLLUM J MOGUL M PHILLIPS C RODEY G WINGARD JR WINTON E YEAGER AM DEVINE S
Citation: K. Zeder et al., IMPACT OF DONOR LYMPHOCYTE INFUSION FOR HEMATOLOGICAL MALIGNANCY RELAPSED AFTER ALLOGENEIC BONE-MARROW TRANSPLANTATION, Cancer research, therapy & control, 5(4), 1998, pp. 221-228
CD34 ENUMERATION IN A MULTICENTER STUDY
Authors: BEVERIDGE R GELLER RB GIGUERE J HARDEN EA JANSEN J JOHNSON DB MENASHE JI RIFKIN RM SAYRE RL SHOGAN JE STRNAD CM
Citation: R. Beveridge et al., CD34 ENUMERATION IN A MULTICENTER STUDY, Journal of hematotherapy, 6(4), 1997, pp. 285-286
GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR INTERLEUKIN-3 FUSIONPROTEIN VERSUS GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR AFTERAUTOLOGOUS BONE-MARROW TRANSPLANTATION FOR NON-HODGKINS-LYMPHOMA - RESULTS OF A RANDOMIZED DOUBLE-BLIND TRIAL
Authors: VOSE JM PANDITE AN BEVERIDGE RA GELLER RB SCHUSTER MW ANDERSON JE LEMAISTRE CF AHMED T GRANENA A KEATING A RANADA JMF STIFF PJ TABBARA I LONGO W COPELAN EA NICHOLS C SMITH A TOPOLSKY DL BIERMAN PJ LEBSACK ME LANGE M GARRISON L
Citation: Jm. Vose et al., GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR INTERLEUKIN-3 FUSIONPROTEIN VERSUS GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR AFTERAUTOLOGOUS BONE-MARROW TRANSPLANTATION FOR NON-HODGKINS-LYMPHOMA - RESULTS OF A RANDOMIZED DOUBLE-BLIND TRIAL, Journal of clinical oncology, 15(4), 1997, pp. 1617-1623
ALLOGENEIC BONE-MARROW TRANSPLANTATION WITH MATCHED UNRELATED DONORS FOR PATIENTS WITH HEMATOLOGIC MALIGNANCIES USING A PREPARATIVE REGIMENOF HIGH-DOSE CYCLOPHOSPHAMIDE AND FRACTIONATED TOTAL-BODY IRRADIATION
Authors: GELLER RB DEVINE SM OTOOLE K PERSONS L KELLER J MAUER D HOLLAND HK DIX SP PIOTTI M REDEI I CONNAGHAN G HEFFNER LT HILLYER CD WALLER EK WINTON EF WINGARD JR
Citation: Rb. Geller et al., ALLOGENEIC BONE-MARROW TRANSPLANTATION WITH MATCHED UNRELATED DONORS FOR PATIENTS WITH HEMATOLOGIC MALIGNANCIES USING A PREPARATIVE REGIMENOF HIGH-DOSE CYCLOPHOSPHAMIDE AND FRACTIONATED TOTAL-BODY IRRADIATION, Bone marrow transplantation, 20(3), 1997, pp. 219-225
CD34 EXPRESSION ON ACUTE MYELOCYTIC-LEUKEMIA CELLS
Authors: GELLER RB BRAY RA
Citation: Rb. Geller et Ra. Bray, CD34 EXPRESSION ON ACUTE MYELOCYTIC-LEUKEMIA CELLS, Leukemia research, 21(5), 1997, pp. 387-389
COMPARISON OF THE EFFICACY AND ASSOCIATED RESOURCE UTILIZATION BETWEEN CYCLOPHOSPHAMIDE (CY) COMBINED WITH G-CSF OR GM-CSF FOR MOBILIZATIONOF AUTOLOGOUS PERIPHERAL-BLOOD PROGENITOR CELLS (PBPC)
Authors: DIX SP CORD MK HOWARD SJ COON JL BELT RJ GELLER RB
Citation: Sp. Dix et al., COMPARISON OF THE EFFICACY AND ASSOCIATED RESOURCE UTILIZATION BETWEEN CYCLOPHOSPHAMIDE (CY) COMBINED WITH G-CSF OR GM-CSF FOR MOBILIZATIONOF AUTOLOGOUS PERIPHERAL-BLOOD PROGENITOR CELLS (PBPC), Blood, 90(10), 1997, pp. 4211-4211
SAFETY AND EFFICACY OF A CONTINUOUS-INFUSION, PATIENT-CONTROLLED ANTIEMETIC PUMP TO FACILITATE OUTPATIENT ADMINISTRATION OF HIGH-DOSE CHEMOTHERAPY (HDC)
Authors: DIX SP CORD MK HOWARD SJ COON JL BELT RJ GELLER RB
Citation: Sp. Dix et al., SAFETY AND EFFICACY OF A CONTINUOUS-INFUSION, PATIENT-CONTROLLED ANTIEMETIC PUMP TO FACILITATE OUTPATIENT ADMINISTRATION OF HIGH-DOSE CHEMOTHERAPY (HDC), Blood, 90(10), 1997, pp. 981-981
MINIMUM RESOURCE UTILIZATION FOR PATIENTS (PTS) WITH BREAST-CANCER, LYMPHOMA, OR MULTIPLE-MYELOMA (MM) UNDERGOING MOBILIZATION (MOB) AND HIGH-DOSE CHEMOTHERAPY (HDC) FOLLOWED BY PERIPHERAL-BLOOD STEM-CELL TRANSPLANTS (PBSCT) AS OUTPATIENTS
Authors: GELLER RB DIX SP BELT RJ CORD MK HOWARD SJ COON JL
Citation: Rb. Geller et al., MINIMUM RESOURCE UTILIZATION FOR PATIENTS (PTS) WITH BREAST-CANCER, LYMPHOMA, OR MULTIPLE-MYELOMA (MM) UNDERGOING MOBILIZATION (MOB) AND HIGH-DOSE CHEMOTHERAPY (HDC) FOLLOWED BY PERIPHERAL-BLOOD STEM-CELL TRANSPLANTS (PBSCT) AS OUTPATIENTS, Blood, 90(10), 1997, pp. 1648-1648
MINIMAL TOXICITY AND MORTALITY IN HIGH-RISK BREAST-CANCER PATIENTS RECEIVING HIGH-DOSE CYCLOPHOSPHAMIDE, THIOTEPA, AND CARBOPLATIN PLUS AUTOLOGOUS MARROW STEM-CELL TRANSPLANTATION AND COMPREHENSIVE SUPPORTIVE CARE
Authors: HOLLAND HK DIX SP GELLER RB DEVINE SM HEFFNER LT CONNAGHAN DG HILLYER CD HUGHES LL MILLER RL MOORE MR WINTON EF WINGARD JR
Citation: Hk. Holland et al., MINIMAL TOXICITY AND MORTALITY IN HIGH-RISK BREAST-CANCER PATIENTS RECEIVING HIGH-DOSE CYCLOPHOSPHAMIDE, THIOTEPA, AND CARBOPLATIN PLUS AUTOLOGOUS MARROW STEM-CELL TRANSPLANTATION AND COMPREHENSIVE SUPPORTIVE CARE, Journal of clinical oncology, 14(4), 1996, pp. 1156-1164
USE OF CYTOKINES IN THE TREATMENT OF ACUTE MYELOCYTIC-LEUKEMIA - A CRITICAL-REVIEW
Authors: GELLER RB
Citation: Rb. Geller, USE OF CYTOKINES IN THE TREATMENT OF ACUTE MYELOCYTIC-LEUKEMIA - A CRITICAL-REVIEW, Journal of clinical oncology, 14(4), 1996, pp. 1371-1382
LONG-TERM FOLLOW-UP OF EDELFOSINE PURGING FOR AUTOLOGOUS BONE-MARROW TRANSPLANTATION (ABMT) IN ACUTE-LEUKEMIA
Authors: VOGLER WR BERDEL WE WINTON EF GORDON DS GELLER RB HEFFNER LT BROCHSTEIN JA BEVERIDGE RA DALTON WS MILLER KB LAZARUS HM
Citation: Wr. Vogler et al., LONG-TERM FOLLOW-UP OF EDELFOSINE PURGING FOR AUTOLOGOUS BONE-MARROW TRANSPLANTATION (ABMT) IN ACUTE-LEUKEMIA, Experimental hematology, 24(9), 1996, pp. 615-615
SELECTION AND TRANSPLANTATION OF AUTOLOGOUS CD34-BLOOD STEM-CELLS IN NON-HODGKINS-LYMPHOMA USING HIGH-SPEED FLUORESCENCE-ACTIVATED CELL SORTING( PERIPHERAL)
Authors: HOLLAND HK FLEMING WH WALLER EK GELLER RB CONNAGHAN DG DEVINE SD YEAGER AM
Citation: Hk. Holland et al., SELECTION AND TRANSPLANTATION OF AUTOLOGOUS CD34-BLOOD STEM-CELLS IN NON-HODGKINS-LYMPHOMA USING HIGH-SPEED FLUORESCENCE-ACTIVATED CELL SORTING( PERIPHERAL), Experimental hematology, 24(9), 1996, pp. 631-631
MARROW TRANSPLANTATION FROM UNRELATED DONORS (UDT) IN PATIENTS WITH APLASTIC-ANEMIA (AA) WHO HAVE FAILED IMMUNOSUPPRESSIVE THERAPY
Authors: DEEG HJ AMYLON M COLLINS R CHAUNCY T BURDACH S KAIZER H GELLER RB COPELAN E STORB R ANASETTI C HOWE C MUELLER BA
Citation: Hj. Deeg et al., MARROW TRANSPLANTATION FROM UNRELATED DONORS (UDT) IN PATIENTS WITH APLASTIC-ANEMIA (AA) WHO HAVE FAILED IMMUNOSUPPRESSIVE THERAPY, Experimental hematology, 24(9), 1996, pp. 652-652
TACROLIMUS (FK506)-INDUCED CEREBRAL BLINDNESS FOLLOWING BONE-MARROW TRANSPLANTATION
Authors: DEVINE SM NEWMAN NJ SIEGEL JL JOSEPH GJ GEIS TC SCHNEIDER JA GELLER RB WINGARD JR
Citation: Sm. Devine et al., TACROLIMUS (FK506)-INDUCED CEREBRAL BLINDNESS FOLLOWING BONE-MARROW TRANSPLANTATION, Bone marrow transplantation, 18(3), 1996, pp. 569-572
ASSOCIATION OF BUSULFAN AREA-UNDER-THE-CURVE WITH VENOOCCLUSIVE DISEASE FOLLOWING BMT
Authors: DIX SP WINGARD JR MULLINS RE JERKUNICA I DAVIDSON TG GILMORE CE YORK RC LIN LS DEVINE SM GELLER RB HEFFNER LT HILLYER CD HOLLAND HK WINTON EF SARAL R
Citation: Sp. Dix et al., ASSOCIATION OF BUSULFAN AREA-UNDER-THE-CURVE WITH VENOOCCLUSIVE DISEASE FOLLOWING BMT, Bone marrow transplantation, 17(2), 1996, pp. 225-230
EVALUATION OF THE DRUG-INTERACTION BETWEEN INTRAVENOUS HIGH-DOSE FLUCONAZOLE AND CYCLOSPORINE OR TACROLIMUS IN BONE-MARROW TRANSPLANT PATIENTS
Authors: OSOWSKI CL DIX SP LIN LS MULLINS RE GELLER RB WINGARD JR
Citation: Cl. Osowski et al., EVALUATION OF THE DRUG-INTERACTION BETWEEN INTRAVENOUS HIGH-DOSE FLUCONAZOLE AND CYCLOSPORINE OR TACROLIMUS IN BONE-MARROW TRANSPLANT PATIENTS, Transplantation, 61(8), 1996, pp. 1268-1272
FEASIBILITY OF 2ND MYELOABLATIVE THERAPY FOLLOWED BY MATCHED UNRELATED DONOR (MUD) TRANSPLANT FOR PATIENTS WITH HEMATOLOGIC MALIGNANCIES WHO RELAPSE AFTER AUTOLOGOUS BONE-MARROW TRANSPLANTATION (ABMT)
Authors: REDEI I GELLER RB OTOOLE K DEVINE S HOLLAND HK WINGARD JR YEAGER AM
Citation: I. Redei et al., FEASIBILITY OF 2ND MYELOABLATIVE THERAPY FOLLOWED BY MATCHED UNRELATED DONOR (MUD) TRANSPLANT FOR PATIENTS WITH HEMATOLOGIC MALIGNANCIES WHO RELAPSE AFTER AUTOLOGOUS BONE-MARROW TRANSPLANTATION (ABMT), Blood, 88(10), 1996, pp. 3846-3846
SELECTION AND TRANSPLANTATION OF AUTOLOGOUS CD34-BLOOD STEM-CELLS IN NON-HODGKINS-LYMPHOMA USING HIGH-SPEED FLUORESCENCE-ACTIVATED CELL SORTING( PERIPHERAL)
Authors: HOLLAND HK FLEMING WH WALLER EK CONNAGHAN DG GELLER RB WINGARD JR YEAGER AM
Citation: Hk. Holland et al., SELECTION AND TRANSPLANTATION OF AUTOLOGOUS CD34-BLOOD STEM-CELLS IN NON-HODGKINS-LYMPHOMA USING HIGH-SPEED FLUORESCENCE-ACTIVATED CELL SORTING( PERIPHERAL), Blood, 88(10), 1996, pp. 1616-1616
RE - SEVERE INTERACTION BETWEEN METHOTREXATE AND A MACROLIDE-LIKE ANTIBIOTIC
Authors: DIX SP DEVINE SM GELLER RB WINGARD JR
Citation: Sp. Dix et al., RE - SEVERE INTERACTION BETWEEN METHOTREXATE AND A MACROLIDE-LIKE ANTIBIOTIC, Journal of the National Cancer Institute, 87(21), 1995, pp. 1641-1642
RANDOMIZED TRIAL OF LOPERAMIDE VERSUS DOSE-ESCALATION OF OCTREOTIDE ACETATE FOR CHEMOTHERAPY-INDUCED DIARRHEA IN BONE-MARROW TRANSPLANT ANDLEUKEMIA PATIENTS
Authors: GELLER RB GILMORE CE DIX SP LIN LS TOPPING DL DAVIDSON TG HOLLAND HK WINGARD JR
Citation: Rb. Geller et al., RANDOMIZED TRIAL OF LOPERAMIDE VERSUS DOSE-ESCALATION OF OCTREOTIDE ACETATE FOR CHEMOTHERAPY-INDUCED DIARRHEA IN BONE-MARROW TRANSPLANT ANDLEUKEMIA PATIENTS, American journal of hematology, 50(3), 1995, pp. 167-172
ENCEPHALOPATHY IS THE DOSE-LIMITING TOXICITY OF INTRAVENOUS HEPSULFAM- RESULTS OF A PHASE-I TRIAL IN PATIENTS WITH ADVANCED HEMATOLOGICAL MALIGNANCIES
Authors: LARSON RA GELLER RB JANISCH L MILTON J GROCHOW LB RATAIN MJ
Citation: Ra. Larson et al., ENCEPHALOPATHY IS THE DOSE-LIMITING TOXICITY OF INTRAVENOUS HEPSULFAM- RESULTS OF A PHASE-I TRIAL IN PATIENTS WITH ADVANCED HEMATOLOGICAL MALIGNANCIES, Cancer chemotherapy and pharmacology, 36(3), 1995, pp. 204-210
ENRICHMENT OF CD34-CELL PRODUCTS OBTAINED FROM HAPLOIDENTICAL NORMAL DONORS BY APHERESIS OF G-CSF MOBILIZED PERIPHERAL-BLOOD CELLS AND COLLECTION OF BONE-MARROW( CELLS AND DEPLETION OF CD3+ CELLS FROM HEMATOPOIETIC STEM)
Authors: HOLLAND HK YEAGER AM GELLER RB WINGARD JR MCCOLLUM J FORTE KJ MOGUL MJ JACOBS CA BERENSON RJ
Citation: Hk. Holland et al., ENRICHMENT OF CD34-CELL PRODUCTS OBTAINED FROM HAPLOIDENTICAL NORMAL DONORS BY APHERESIS OF G-CSF MOBILIZED PERIPHERAL-BLOOD CELLS AND COLLECTION OF BONE-MARROW( CELLS AND DEPLETION OF CD3+ CELLS FROM HEMATOPOIETIC STEM), Experimental hematology, 23(8), 1995, pp. 759-759
THROMBOTIC THROMBOCYTOPENIC PURPURA ASSOCIATED WITH FK506 FOLLOWING BONE-MARROW TRANSPLANTATION
Authors: GHARPURE VS DEVINE SM HOLLAND HK GELLER RB OTOOLE K WINGARD JR
Citation: Vs. Gharpure et al., THROMBOTIC THROMBOCYTOPENIC PURPURA ASSOCIATED WITH FK506 FOLLOWING BONE-MARROW TRANSPLANTATION, Bone marrow transplantation, 16(5), 1995, pp. 715-716
CONSENSUS STATEMENT - OCTREOTIDE DOSE TITRATION IN SECRETORY DIARRHEA- DIARRHEA MANAGEMENT CONSENSUS DEVELOPMENT PANEL
Authors: HARRIS AG ODORISIO TM WOLTERING EA ANTHONY LB BURTON FR GELLER RB GRENDELL JH LEVIN B REDFERN JS
Citation: Ag. Harris et al., CONSENSUS STATEMENT - OCTREOTIDE DOSE TITRATION IN SECRETORY DIARRHEA- DIARRHEA MANAGEMENT CONSENSUS DEVELOPMENT PANEL, Digestive diseases and sciences, 40(7), 1995, pp. 1464-1473
AML EXPRESSING LYMPHOID-ASSOCIATED ANTIGENS
Authors: LAUNDER TM FARHI DC BRAY RA HOLLAND HK GELLER RB
Citation: Tm. Launder et al., AML EXPRESSING LYMPHOID-ASSOCIATED ANTIGENS, Laboratory investigation, 72(1), 1995, pp. 114-114
Risultati: 1-25 | 26-50 | 51-51